NR1H4 and metabolic dysfunction-associated steatohepatitis: We further show that pharmacological activation of FXR by hammerhead-type agonists induces a liver-specific enhancer-derived lncRNA, which we named FincoR, that contributes to reduction of NASH pathologies in mice.